Abstract
The incidence of cytomegalovirus (CMV) infection was significantly increased due to the impaired immune function of the patients after hematopoietic stem cell transplantation (HSCT). Anti CMV drugs mainly include ganciclovir and foscarnet, which will decline the immune function of the patients and easily lead to a further virus resistance, and the late-onset CMV disease may actually increase. Therefore, cellular immunotherapy has become a new prevention and therapy of CMV, and the phase Ⅱ and phase Ⅲ clinical trials are being carried out in many countries. It is confirmed that cellular immunotherapy is effective on CMV infection and it is rarely caused the risk of graft versus host disease(GVHD). This article reviews literatures on the cellular immunotherapy of CMV infection. Key words: Cytomegalovirus; Immunotherapy; Hematopoietic stem cell transplantation
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Transfusion and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
